[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370609-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-370609-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","swisnf-atpase-silenced-hlf-potentiates-lung-metastasis-in-solid-cancers-research-paper","SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers - Research paper","","Metastasis drives most cancer deaths, yet the mechanisms behind lung dissemination remain unclear. In clear cell renal cell carcinoma, an in vivo genome-wide CRISPR-Cas9 screen identifies HLF as a potent suppressor of lung metastasis. HLF depletion increases migration and lung metastasis, while HLF overexpression reverses these effects. In patients, HLF is reduced at metastatic sites and linked to BRG1-mediated epigenetic silencing, affecting migration via LPXN and collagen–actin coupling through Paxillin.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/swisnf-atpase-silenced-hlf-potentiates-lung-metastasis-in-solid-cancers-research-paper/370609/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/swisnf-atpase-silenced-hlf-potentiates-lung-metastasis-in-solid-cancers-research-paper/370609.png","ImageObject",300,407,{"name":42,"@type":43},"Sarah ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study identify as regulating lung metastasis in solid cancers?","Question",{"text":63,"@type":64},"The study identifies HLF as a potent suppressor of lung metastasis, revealed through an in vivo genome-wide CRISPR-Cas9 screen in clear cell renal cell carcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do HLF expression changes affect tumor cell behavior?",{"text":68,"@type":64},"HLF depletion enhances cell migration and lung metastasis, whereas HLF overexpression abrogates these effects.",{"name":70,"@type":61,"acceptedAnswer":71},"How is HLF linked to epigenetic control in metastatic sites?",{"text":72,"@type":64},"HLF expression is reduced at metastatic sites and associates with epigenetic silencing mediated by the SWI/SNF ATPase subunit BRG1.",{"name":74,"@type":61,"acceptedAnswer":75},"What therapeutic approach is suggested by the findings?",{"text":76,"@type":64},"Targeting the BRG1–HLF axis is proposed as a promising therapeutic strategy, supported by reduced invasion after HLF overexpression or pharmacological inhibition of BRG1.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},370609,1791107713,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Article [https://doi.org/10.1038/s41467-025-60329-9](https://doi.org/10.1038/s41467-025-60329-9)  \nSWI/SNF ATPase silenced HLF potentiateslung metastasis in solid cancers  \nReceived: 4 November 2024  \n\n| Accepted: 20 May 2025 |\n| --- |\n| |\n| Check for updates |\n\nJin Zhou 1, Austin Hepperla 2,3,4, Jeremy M. Simon 2,3,4, Kangsan Kim1, Qing Hu 1, Chuanhai Zhang5, Lei Dong 6, Lianxin Hu 1, Cheng Zhang1, Chengheng Liao 1, Alice Fang1, Yayoi Adachi1, Haoyong Fu1, Tao Wang1, Qian Liang1, Fangzhou Zhao1, Hongyi Liu1, Masashi Takeda1, Jun Fang1, Hua Zhong1, Peter Ly 1, Lu Wang 7, Payal Kapur 1,8, Lin Xu 6, Liwei Jia1, SrinivasMalladi 1, James Brugarolas 8,9, M. Celeste Simon 10 , BoLi 11  & Qing Zhang 1,12   \nMetastasis is the main cause of cancer-related deaths, yet the underlying mechanisms remain elusive. Here, using clear cell renal cell carcinoma (ccRCC), a tumor type with frequent lung metastases, we conduct an in vivo genome-wide CRISPR-Cas9 screen and identify HLF as a potent suppressor of lung metastasis. HLF depletion enhances ccRCC cell migration and lung metastasis, whereas HLF overexpression abrogates these effects. In ccRCC patients, HLF expression is reduced at metastatic sites and associates with epigenetic silencing mediated by the SWI/SNFATPase subunit BRG1. HLF levels negatively correlate with migration potential in collagen. Mechanistically, HLF regulates LPXN expression, modulating the integration of collagen’s mechanical cues with the actin cytoskeleton through Paxillin, thereby suppressing cancer cell migration and lung metastasis. Overexpression of HLF or pharmacological inhibition of BRG1 reduces cell invasion across multiple cancer types. Ourﬁndings suggest that targeting the BRG1-HLF axis offers a promising therapeutic strategy for combating metastatic cancers.  \nMore than 90% of cancer-related deaths result from tumor metastases1, while the underlying mechanisms remain poorly understood. The lung is a common metastatic site for various cancers, including renal cancer. In clear cell renal cell carcinoma (ccRCC), the most common type of renal  \ncancer (>80%), the lung is the primary site of metastasis (70%)2. The ﬁveyear survival rate for ccRCC patients with disease conﬁned to the kidney is approximately 90%, whereas it drops to under 20% for metastatic ccRCC3,4. Using ccRCC as a model, we performed an in vivo genetic  \n1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 3Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. 4UNC Neuroscience Center, University of North Carolina, Chapel Hill, NC, USA. 5Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 6Quantitative Biomedical Research Center, Department of Health Data Science and Biostatistics, Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. 7Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 8Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. 9Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 10Abramson Family Cancer Research Institute, Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA, USA. 11Department of Biochemistry and Molecular Biology, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, PR China. 12Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. e-mail: [celeste2@pennmedicine.upenn.edu](celeste2@pennmedicine.upenn.edu); [libo47@smu.edu.cn](libo47@smu.edu.cn);  \n[Qing.Zhang@UTSouthwestern.edu](Qing.Zhang@UTSouthwestern.edu)  \nscreening","cbCais1Rt73qt3WK","https://ap.wps.com/l/cbCais1Rt73qt3WK","pdf",4766870,"English","# Background and clinical relevance\n## Lung metastasis in clear cell renal cell carcinoma\n# Experimental strategy and discovery\n## In vivo genome-wide CRISPR-Cas9 screening\n## Identification of HLF as a regulator\n# Mechanistic insights\n## Epigenetic silencing via BRG1\n## HLF control of LPXN and collagen–actin signaling\n# Functional validation and therapeutic implications\n## HLF overexpression and BRG1 inhibition\n## Targeting the BRG1–HLF axis against metastasis","[{\"question\":\"What does the study identify as regulating lung metastasis in solid cancers?\",\"answer\":\"The study identifies HLF as a potent suppressor of lung metastasis, revealed through an in vivo genome-wide CRISPR-Cas9 screen in clear cell renal cell carcinoma.\"},{\"question\":\"How do HLF expression changes affect tumor cell behavior?\",\"answer\":\"HLF depletion enhances cell migration and lung metastasis, whereas HLF overexpression abrogates these effects.\"},{\"question\":\"How is HLF linked to epigenetic control in metastatic sites?\",\"answer\":\"HLF expression is reduced at metastatic sites and associates with epigenetic silencing mediated by the SWI/SNF ATPase subunit BRG1.\"},{\"question\":\"What therapeutic approach is suggested by the findings?\",\"answer\":\"Targeting the BRG1–HLF axis is proposed as a promising therapeutic strategy, supported by reduced invasion after HLF overexpression or pharmacological inhibition of BRG1.\"}]","SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers - Research paper | PDF",1790189449,48,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7352cb7a707eb4d91c8379be0e4cfa5.webp",983,1305,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10c84fb7f11f88d3f8dab13f11f63971.webp",982,1304,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54f1634f93be3896393a5b2b292d59d5.webp",981,1303,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e47a46d1960a17f4610b781418ecc733.webp",980,1301]